食管癌锁骨上淋巴结转移放疗疗效及预后因素分析  

Analysis of Therapeutic Effect and Prognosis of Radiotherapy for Patients with Esophageal Carcinoma with Supraclavicular Lymph Node Metastasis

作　　者：甄婵军[1] 周志国[1] 宋玉芝[1] 乔学英[1] 

机构地区：[1]河北医科大学第四医院放疗五病区,石家庄050011

出　　处：《肿瘤防治研究》2013年第1期90-94,共5页Cancer Research on Prevention and Treatment

基　　金：河北卫生厅医学科学研究重点课题(07290);河北省普通高校强势特色学科资助项目(2005-52)

摘　　要：目的回顾性分析胸段食管癌锁骨上淋巴结转移患者的放疗疗效及其预后影响因素。方法回顾2005年1月—2009年12月经组织学证实的锁骨上淋巴结转移的胸段食管癌病例152例,其中食管原发灶采用放射治疗患者95例,手术治疗57例;食管原发灶治疗后锁骨上淋巴结转移81例,初诊时发现71例;141例患者锁骨上淋巴结行放射治疗,11例患者未行放射治疗。结果全组患者中位随访时间为17.5月(2～77月)。放射治疗后近期疗效评价达CR、PR、NC及PD的分别为52.5%(74/141)、41.8%(59/141)、3.6%(5/141)和2.1%(3/141)。1、2、3年生存率分别为51.3%、26.6%、17.3%。单侧转移与双侧转移患者1、3年生存率分别为54.0%、17.6%和26.7%、13.3%(P=0.033)。转移灶放疗剂量≥60Gy和<60Gy患者的1、3年生存率分别为61.5%、21.7%和12.5%、0(P<0.01)。单侧锁骨上区淋巴结转移的患者中,健侧锁骨上区预防照射与未行预防照射患者的1、3年生存率分别为53.7%、12.3%和56.3%、20.6%(P=0.939)。多因素分析示患者的年龄、锁骨上淋巴结转移时间、锁骨上淋巴结转移时食管原发灶控制情况及是否合并内脏转移对预后的影响差异有统计学意义(P=0.007、P=0.009、P=0.008、P<0.01)。结论放射治疗是食管癌锁骨上淋巴结转移的有效治疗手段;锁骨上转移灶放射治疗范围以累及野为宜,剂量60～70Gy;患者的年龄、锁骨上淋巴结转移时间、食管原发灶的控制情况及是否合并内脏转移对患者的预后有影响。Objective To explore the factors affecting the prognosis of radiotherapy for esophageal carcino- ma with supraclavicular lymph node metastasis. Methods One hundred and fifty-two esophageal carcino- ma patients with supraelavicular lymph node metastases who were admitted to the Fourth Hospital of He- bei Medical University from January 2005 to December 2009 were enrolled. A total of 95 patients with primary tumors received radiotherapy,whereas 57 patients underwent surgery. Eighty one patients were found supraclavicular lymph nodes metastasis after the treatment of primary esophageal carcinoma,and 71 patients were found with metastasis when they were diagnosed. A total of 141 patients with supraclavicu- lar lymph node metastasis received radiotherapy,whereas 11 did not. Results Follow-up time was 2 to 77 months with a median follow-up time of 17.5 months. After radiotherapy for the supraclavicular lymph- node,the rate of CR,PR,NR and PD was 52.5% ,41.8% ,3.6% and 2. 1% respectively. The 1 ,2-,3- year overall survival rates were 51.3% ,26.6% and 17.3%. The 1-year survival rates for one-side and both sides were 54.0% and 26.70/00 ,and the 3-year survival rates were 17.6% and 13.3% （P = 0. 033）. The 1-,3-year survival rates of patients with supraclavicular lymph nodes metastasis subjected the dose more than 60 Gy were 61. 50%,21.7% ,and that of less than 60 Gy were 12.5%,0% （P〈0.01）,respec tively. The 1-,3-year survival rates of patients with contralateral supraelavicular prophylactic irradiation were 53.7 %, 12.3 %, and that of without prophylactic irradiation were 56.3 %, 2（1.6 % （ P = 0. 939）, respectively. Multivariate analysis revealed that age,time of supraclavicular lymphnode metastasis, whether the primary tumors were controlled and visceral metastasis were independent factors for the survivals （P = 0. 007,0. 009,0. 008, 〈0.01 ）. Conclusion The patients of esophageal carcinoma with supraclavicular lymph node metastasis can benefit from radiotherapy. The suitable dose of supraclavicular

关 键 词：食管癌 锁骨上淋巴结转移 放射治疗 预后 

分 类 号：R735.1[医药卫生—肿瘤] R731.55[医药卫生—临床医学]